Key Highlights - CB4211
We believe CB4211 offers a differentiated approach to treating nonalcoholic steatohepatitis (NASH) and obesity.
- Is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP) that plays a key role in regulating metabolism
- Has resulted in significant impacts on NASH and obesity in multiple preclinical models
- Has been shown in a clinical study to significantly reduce ALT and AST, key biomarkers of liver damage, as well as glucose levels compared to placebo
- Resulted in a trend towards lower body weight compared to placebo in a clinical trial